Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will showcase 46 abstracts, ...

Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...

Reports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024.Reports record GAAP diluted EPS ...

Baxter updated its full-year 2025 guidance, expecting total sales growth of 4% to 5% on a reported basis, incorporating approximately $320 million of anticipated MSA revenues from Vantive and a 50 ...

PepGen shifts focus to PGN-EDODM1 for Myotonic Dystrophy Type 1 after discontinuing PGN-EDO51 for Duchenne Muscular Dystrophy ...

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma ...

Key opportunities in the clinical trial platform market include leveraging AI and machine learning for enhanced trial design ...

Takeda (TSE:4502/NYSE:TAK) today announced that the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older, as prescribed, who are ...

Scientists are learning more about this leading complication of childbirth. Treatments are improving and doctors can test for ...

Basel, 23 October 2025 Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF) in the first nine months, driven by high demand for our innovative medicines and diagnostics.Pharmaceuticals ...

Gold Rate Today, October 22: Gold and silver on Wednesday fell, amid signs of easing US-China trade tensions and as investors took advantage of bullion’s recent record rally to take profits while ...